Cited 16 times in
Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박무석 | - |
dc.date.accessioned | 2020-09-28T11:42:41Z | - |
dc.date.available | 2020-09-28T11:42:41Z | - |
dc.date.issued | 2020-05 | - |
dc.identifier.issn | 0741-238X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/179260 | - |
dc.description.abstract | Aim: The efficacy and safety of pirfenidone have been previously demonstrated in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF). However, the effect of pirfenidone in patients with advanced IPF remains unclear. Here, we investigated the effects of pirfenidone against advanced IPF in a real-world setting. Methods: A prospective nationwide post-marketing study was conducted on 258 patients from 10 Korean institutions. Patients with a predicted forced vital capacity (FVC) less than 50% or a diffusing capacity of the lung for carbon monoxide (DLco) less than 35% at baseline were classified as the advanced IPF group. Results: Of 219 patients included in the analysis, the majority were male (76.3%); the mean age was 67.3 years, and the advanced group accounted for 17.8% of the patients. The median treatment duration was 298 days. Among the subjects, 86.3% experienced adverse events (AEs), of which a decreased appetite (32.4%) and a photosensitivity reaction (13.7%) were the most frequent. The incidence of AEs was similar between the advanced and non-advanced groups (92.3% vs. 85.0%, respectively; p = 0.229). Although the overall discontinuation rate was higher in the advanced group than in the non-advanced group (74.4% vs. 50.0%, respectively; p = 0.006), the percentages of the patients who discontinued treatment as a result of AEs were similar in both groups (20.5% vs. 23.3%, respectively; p = 0.704). In all patients, the rates of decline in the predicted FVC and DLco over 48 weeks were - 4.3 ± 1.3% and - 4.4 ± 1.7%, respectively. There was no between-group difference in the rate of lung function decline. Conclusions: Pirfenidone used for the treatment of patients with IPF in a real-world setting was well tolerated, with an acceptable safety profile and a consistent therapeutic effect, regardless of the disease severity. Trial registration: ClinicalTrials.gov NCT03761082; the trial was retrospectively registered on December 3, 2018. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Health Communications | - |
dc.relation.isPartOf | ADVANCES IN THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Man Pyo Chung | - |
dc.contributor.googleauthor | Moo Suk Park | - |
dc.contributor.googleauthor | In Jae Oh | - |
dc.contributor.googleauthor | Heung Bum Lee | - |
dc.contributor.googleauthor | Young Whan Kim | - |
dc.contributor.googleauthor | Jong Sun Park | - |
dc.contributor.googleauthor | Soo Taek Uh | - |
dc.contributor.googleauthor | Yun Seong Kim | - |
dc.contributor.googleauthor | Yangjin Jegal | - |
dc.contributor.googleauthor | Jin Woo Song | - |
dc.identifier.doi | 10.1007/s12325-020-01328-8 | - |
dc.contributor.localId | A01457 | - |
dc.relation.journalcode | J00048 | - |
dc.identifier.eissn | 1865-8652 | - |
dc.identifier.pmid | 32297284 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs12325-020-01328-8 | - |
dc.subject.keyword | Advanced disease | - |
dc.subject.keyword | Disease progression | - |
dc.subject.keyword | Idiopathic pulmonary fibrosis | - |
dc.subject.keyword | Pirfenidone | - |
dc.subject.keyword | Safety | - |
dc.subject.keyword | Treatment outcome | - |
dc.contributor.alternativeName | Park, Moo Suk | - |
dc.contributor.affiliatedAuthor | 박무석 | - |
dc.citation.volume | 37 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 2303 | - |
dc.citation.endPage | 2316 | - |
dc.identifier.bibliographicCitation | ADVANCES IN THERAPY, Vol.37(5) : 2303-2316, 2020-05 | - |
dc.identifier.rimsid | 67466 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.